Baxter International (BAX) has released compelling new data revealing that expanded hemodialysis (HDx therapy), facilitated by the Theranova dialyzer, is associated with an approximately 25% reduction in all-cause mortality risk over a span of up to four years compared to high-flux hemodialysis. This insight comes from a 48-month observational cohort study involving 1,092 dialysis patients across 11 Baxter Renal Care Services Centers in Colombia.
"This four-year study's results are highly encouraging, showcasing approximately 25% lower mortality rates for chronic kidney patients using Baxter's Theranova dialyzer," said Peter Rutherford, Vice President of Medical Affairs for Kidney Care at Baxter.
For more health news, visit rttnews.com.
